ArticleMicroorganisms2016
Achromobacter Species Isolated from Cystic Fibrosis Patients Reveal Distinctly Different Biofilm Morphotypes.
Article in Microorganisms, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Early and matureBiofilm · 2026Article
- Analysis of virulence of the emerging opportunistic human pathogen Achromobacter in a zebrafish embryo model.BMC microbiology · 2026Article
- Genomic heterogeneity and lineage-specific beta-lactamases in recurrentEmerging microbes & infections · 2025Article
- Assessment of the Anti-Biofilm Effect of Cefiderocol Against 28 Clinical Strains of Multidrug-Resistant Gram-Negative Bacilli.Antibiotics (Basel, Switzerland) · 2025Article
- In-hospital areas with distinct maintenance and staff/patient traffic have specific microbiome profiles, functions, and resistomes.mSystems · 2024Article
- Isolation and characterization of a newly chrysene-degrading Achromobacter aegrifaciens.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Exoproducts of the Most CommonMicrobiology spectrum · 2023Article
- In Vivo Inflammation Caused byInternational journal of molecular sciences · 2023Article
- Mucoid Staphylococcus haemolyticus: an unheeded multidrug-resistant pathogen.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Polymyxin Resistance and Heteroresistance Are Common in Clinical Isolates ofMicrobiology spectrum · 2023Article
- Polymeric Packaging Applications for Seafood Products: Packaging-Deterioration Relevance, Technology and Trends.Polymers · 2022Review
- TheMicrobiology spectrum · 2022Article
- Article
- Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?ACS applied materials & interfaces · 2022Article
- Infectious Uveitis in Horses and New Insights in Its Leptospiral Biofilm-Related Pathogenesis.Microorganisms · 2022Review
- Characterization of theFrontiers in cellular and infection microbiology · 2022Article
- Gene Analysis ofMicroorganisms · 2021Article
- Adaptive Interactions ofPathogens (Basel, Switzerland) · 2021Article
- Genomic characterization ofMicrobial genomics · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achromobacter species have attracted attention as emerging pathogens in cystic fibrosis. The clinical significance of Achromobacter infection is not yet fully elucidated; however, their intrinsic resistance to antimicrobials and ability to form biofilms renders them capable of establishing long-term chronic infections. Still, many aspects of Achromobacter biofilm formation remain uncharacterized. In this study, we characterized biofilm formation in clinical isolates of Achromobacter and investigated the effect of challenging the biofilm with antimicrobials and/or enzymes targeting the extracellular matrix. In vitro biofilm growth and subsequent visualization by confocal microscopy revealed distinctly different biofilm morphotypes: a surface-attached biofilm morphotype of small aggregates and an unattached biofilm morphotype of large suspended aggregates. Aggregates consistent with our in vitro findings were visualized in sputum samples from cystic fibrosis patients using an Achromobacter specific peptide nucleic acid fluorescence in situ hybridization (PNA-FISH) probe, confirming the presence of Achromobacter biofilms in the CF lung. High antibiotic tolerance was associated with the biofilm phenotype, and biocidal antibiotic concentrations were up to 1000 fold higher than for planktonic cultures. Treatment with DNase or subtilisin partially dispersed the biofilm and reduced the tolerance to specific antimicrobials, paving the way for further research into using dispersal mechanisms to improve treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.